Complementary and alternative therapies in skin cancer: A literature review of biologically active compounds - 22/08/19
Cristóbal Saldías-Fuentes, MD, Department of Dermatology, Pontificia Universidad Católica de Chile, Santiago, Chile; Kwokwai Yeung, PharmD, Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Jun Mao, MD, Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Allan Halpern, MD, Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; Cristián Navarrete-Dechent, MD, Department of Dermatology and Melanoma and Skin Cancer Unit, Pontificia Universidad Católica de Chile, Santiago, Chile, and Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Le texte complet de cet article est disponible en PDF.| Commercial support: None identified. |
Vol 81 - N° 4S1
P. AB38 - octobre 2019 Retour au numéro
Article précédent
- Comparison of treatment patterns and health care costs between ixekizumab and adalimumab users among psoriasis patients
- Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?